Stock comparison
Halozyme Therapeutics
Indivior Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
INDV
Indivior Pharmaceuticals
Market cap
$4.68B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | INDV | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 35D | HALO |
| Benjamin Graham | 83A | 30F | HALO |
| Philip Fisher | 65B | 44D | HALO |
| Peter Lynch | 53D | 71B | INDV |
| Joel Greenblatt | 40D | 78B | INDV |
| Charlie Munger | 80C | 50D | HALO |
| Terry Smith | 84A | 46D | HALO |
Side-by-side metrics
| Metric | HALO | INDV |
|---|---|---|
| Market cap | $8.1B | $4.68B |
| P/E (TTM) | 24.0x | 19.0x |
| EV/EBIT | 10.2x | 19.1x |
| ROIC (TTM) | 23.65% | 85.68% |
| Gross margin | 81.24% | 83.11% |
| Net margin | 23.13% | 19.44% |
| Revenue CAGR 5y | 33.23% | 11.87% |
| EPS CAGR 5y | -1.98% | 5.04% |
| Debt / Equity | 1.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 11.87%+64%
- EV/EBIT10.2xvs 19.1x+47%
- Market cap$8.1Bvs $4.68B+42%
- Net margin23.13%vs 19.44%+16%
INDV leads on
- EPS CAGR 5y5.04%vs -1.98%+139%
- Debt / Equity-vs 1.0x+127%
- ROIC (TTM)85.68%vs 23.65%+72%
- P/E (TTM)19.0xvs 24.0x+21%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.